Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Queensland Health
Fuji
Harvard Business School
Fish and Richardson

Generated: September 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,445,485

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,445,485 protect, and when does it expire?

Patent 8,445,485 protects TAVALISSE and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: 8,445,485
Title:Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Inventor(s): Bhamidipati; Somasekhar (Foster City, CA), Singh; Rajinder (Belmont, CA), Sun; Thomas (Fremont, CA), Masuda; Esteban (Menlo Park, CA)
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:13/418,306
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,445,485

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-001 Apr 17, 2018 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-002 Apr 17, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 8,445,485

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 540041 ➤ Sign Up
Canada 2673137 ➤ Sign Up
Denmark 2078026 ➤ Sign Up
European Patent Office 2078026 ➤ Sign Up
European Patent Office 2420505 ➤ Sign Up
Spain 2380551 ➤ Sign Up
Hong Kong 1133257 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Cipla
Queensland Health
McKesson
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.